Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

MCRI On-X Mechanical Heart Valve Gains Aortic Indication

This article was originally published in The Gray Sheet

  • News

Executive Summary

The Medical Carbon Research Institute will not have to perform post-market studies for its On-X prosthetic heart valve, which gained premarket approval from FDA on May 30.

You may also be interested in...



MCRI On-X Prosthetic Valve Approved For Mitral Indication

Medical Carbon Research Institute plans to begin shipping its On-X prosthetic mitral heart valve by May, following supplemental PMA approval on March 6

MCRI On-X Prosthetic Valve Approved For Mitral Indication

Medical Carbon Research Institute plans to begin shipping its On-X prosthetic mitral heart valve by May, following supplemental PMA approval on March 6

ATS Medical To Launch Open Pivot Bileaflet Heart Valve By Nov. 1

Shipments of ATS Medical's Open Pivot bileaflet mechanical heart valve, which received FDA approval Oct. 13, are scheduled to begin before month-end, the company says.

Table

View full table

Tags:
Latest Headlines

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

See All
UsernamePublicRestriction

Register

MT014963

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By